{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:30:43Z","timestamp":1793226643109,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.tjpad.2025.100337","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T15:30:53Z","timestamp":1757086253000},"page":"100337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-3835","authenticated-orcid":false,"given":"David","family":"Greeley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Herskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6010-3544","authenticated-orcid":false,"given":"Fred","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Rock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neils","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9101-5704","authenticated-orcid":false,"given":"SangYun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7058-2396","authenticated-orcid":false,"given":"Tianyang","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1905-5170","authenticated-orcid":false,"given":"Jonathan A.","family":"Busam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9414-0066","authenticated-orcid":false,"given":"Benoit","family":"Tete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai Jun","family":"Choung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3666-1463","authenticated-orcid":false,"given":"Sharon J.","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2025.100337_bib0001","unstructured":"WHO. Fact sheets of dementia 2021 [updated 2017. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"issue":"2","key":"10.1016\/j.tjpad.2025.100337_bib0002","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(01)00476-7","article-title":"New frontiers in Alzheimer's disease genetics","volume":"32","author":"Tanzi","year":"2001","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100337_bib0003","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer's disease: a review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100337_bib0004","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer's disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100337_bib0005","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100337_bib0006","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.neuron.2008.11.007","article-title":"Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis","volume":"60","author":"Small","year":"2008","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100337_bib0007","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/alz.12192","article-title":"Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease","volume":"17","author":"Arnsten","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100337_bib0008","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer's disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100337_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt24","article-title":"Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy","volume":"2","author":"Zotova","year":"2010","journal-title":"Alzheimer Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100337_bib0010","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0891-5849(96)00629-6","article-title":"Oxidative stress hypothesis in Alzheimer's disease","volume":"23","author":"Markesbery","year":"1997","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100337_bib0011","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100337_bib0012","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100337_bib0013","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimer Dis"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100337_bib0014","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100337_bib0015","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1002\/med.21699","article-title":"From combinations to multitarget-directed ligands: a continuum in Alzheimer's disease polypharmacology","volume":"41","author":"Albertini","year":"2021","journal-title":"Med Res Rev"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100337_bib0016","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/nan.12642","article-title":"Invited review - understanding cause and effect in Alzheimer's pathophysiology: implications for clinical trials","volume":"46","author":"Boche","year":"2020","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100337_bib0017","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","article-title":"Polypharmacology by design: a medicinal chemist's perspective on multitargeting compounds","volume":"62","author":"Proschak","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.tjpad.2025.100337_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113818","article-title":"Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease","volume":"176","author":"Zuccarello","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100337_bib0019","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s43587-021-00138-z","article-title":"Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease","volume":"1","author":"Fang","year":"2021","journal-title":"Nat Aging"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100337_bib0020","first-page":"2008","article-title":"Polypharmacological potential of phosphodiesterase 5 inhibitors for the treatment of neurocognitive disorders","volume":"15","author":"Kumar","year":"2024","journal-title":"Aging Dis"},{"issue":"20","key":"10.1016\/j.tjpad.2025.100337_bib0021","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3390\/cells13201720","article-title":"The emerging role of phosphodiesterase 5 inhibition in neurological disorders: the state of the art","volume":"13","author":"Crescioli","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.tjpad.2025.100337_bib0022","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/jlcr.1116","article-title":"Synthesis of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazin1-ylsulfonyl]-2-n-propoxyphenyl}-7-n-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]-[2-14C]pyrimidin-4-one . 2HCl (14C-SK3530. 2 HCl)","volume":"49","author":"Shin","year":"2006","journal-title":"J Label Compd Radiopharm"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100337_bib0023","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13195-022-01034-3","article-title":"Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions","volume":"14","author":"Kang","year":"2022","journal-title":"Alzheimer Res Ther"},{"key":"10.1016\/j.tjpad.2025.100337_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2025.1579411","article-title":"Mirodenafil improves cognitive function by reducing microglial activation and blood\u2013brain barrier permeability in ApoE4 KI mice","volume":"17","author":"Park","year":"2025","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.tjpad.2025.100337_bib0025","article-title":"Therapeutic effects of mirodenafil, a phosphodiesterase 5 inhibitor, on stroke models in rats","author":"Kim","year":"2024","journal-title":"Neurotherapeutics"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100337_bib0026","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1745-7254.2007.00611.x","article-title":"Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats","volume":"28","author":"Yoo","year":"2007","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.tjpad.2025.100337_bib0027","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.med.57.121304.131442","article-title":"Current pharmacotherapy for Alzheimer's disease","volume":"57","author":"Lleo","year":"2006","journal-title":"Annu Rev Med"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100337_bib0028","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.tjpad.2025.100337_bib0029","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure","volume":"6","author":"Holm","year":"1979","journal-title":"Scandinav J Statist"},{"key":"10.1016\/j.tjpad.2025.100337_bib0030","unstructured":"FDA. Approval Package for Exelon Transdermal Patch. 2012."},{"issue":"5","key":"10.1016\/j.tjpad.2025.100337_bib0031","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/brain\/awad042","article-title":"Predicting amyloid PET and tau PET stages with plasma biomarkers","volume":"146","author":"Jack","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.tjpad.2025.100337_bib0032","unstructured":"Mintun MA, eds. Donanemab slows progression of early symptomatic alzheimer's disease in Phase 2 proof of concept trial. AD\/PD; 2021; Vienna."},{"issue":"3","key":"10.1016\/j.tjpad.2025.100337_bib0033","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100337_bib0034","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9030291","article-title":"Visual side effects linked to sildenafil consumption: an update","volume":"9","author":"Aus\u00f3","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.tjpad.2025.100337_bib0035","unstructured":"Athira Pharma Announces Topline Results from Phase 2\/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer\u2019s Disease [press release]. September 03, 2024 2024."},{"issue":"4","key":"10.1016\/j.tjpad.2025.100337_bib0036","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer Dement"},{"issue":"20","key":"10.1016\/j.tjpad.2025.100337_bib0037","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer's disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100337_bib0038","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14283\/jpad.2022.102","article-title":"Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer's disease","volume":"10","author":"Lansdall","year":"2023","journal-title":"J Prev Alzheimer Dis"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725002791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725002791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:15:04Z","timestamp":1759961704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725002791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2274580725002791"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100337","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100337"}}